• Significant Representations

    • A major pharmaceutical company in a California coordinated litigation involving the claim that an H2 receptor antagonist caused patients to develop cancer.
    • A major pharmaceutical company as national coordinating and trial counsel in numerous large product liability and consumer fraud litigations, including separate MDLs involving antidepressant and cholesterol-lowering medications in which our lawyers secured MDL-wide summary judgment based on successful Daubert motions. In both cases, the Daubert and summary judgment rulings were affirmed on appeal and resulted in the complete dismissal of all of the individual lawsuits in these MDLs. See In re Lipitor (Atorvastatin Calcium) Mktg., Sales Practices & Prod. Liab. Litig. (No II) MDL 2502, 892 F.3d 624 (4th Cir. 2018); In re Zoloft (Sertraline Hydrochloride) Prod. Liab. Litig., 858 F.3d 787 (3d Cir. 2017).
    • A major pharmaceutical company as national counsel in lawsuits in a federal MDL and in state courts across the country concerning its prescription opioid pain medications.
    • A major pharmaceutical company in a significant victory when a federal district court dismissed with prejudice an entire MDL on a motion to dismiss. Plaintiffs were third-party payors who sought to recover payments for alleged improper off-label prescriptions of anemia medications. The U.S. Court of Appeals for the Ninth Circuit affirmed.
    • A pharmaceutical and biotechnology company as U.S. national counsel regarding any product liability issues relating to its COVID-19 vaccine.
    • A manufacturing company in product liability litigation involving allegations that a product sold to the military is related to hearing loss suffered by servicemen and women.

    Includes matters handled at Dechert or prior to joining the firm.